Cargando…

Safety, tolerability, pharmacokinetic/pharmacodynamic characteristics of bersiporocin, a novel prolyl‐tRNA synthetase inhibitor, in healthy subjects

Bersiporocin, a novel first‐in‐class prolyl‐tRNA synthetase (PRS) inhibitor currently under clinical development, was shown to exert an antifibrotic effect through the downregulation of collagen synthesis in various pulmonary fibrosis models. The aim of this first‐in‐human, randomized, double‐blind,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Park, Min Young, Bae, Sungyeun, Heo, Jung A, Park, Mihee, Kim, YuKyung, Han, Jumi, Jang, In‐Jin, Yu, Kyung‐Sang, Oh, Jaeseong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10339703/ https://www.ncbi.nlm.nih.gov/pubmed/37095713 http://dx.doi.org/10.1111/cts.13518

Ejemplares similares

Comparison of the Pharmacokinetics, Safety, and Tolerability of Two Empagliflozin Formulations in Healthy Korean Subjects
por: Jiang, Xu, et al.
Publicado: (2023)

Evaluation of Safety, Tolerability and Pharmacokinetic Characteristics of SA001 and Its Active Metabolite Rebamipide after Single and Multiple Oral Administration
por: Bae, Sungyeun, et al.
Publicado: (2023)

Control of fibrosis with enhanced safety via asymmetric inhibition of prolyl‐tRNA synthetase 1
por: Yoon, Ina, et al.
Publicado: (2023)

Halofuginone and other febrifugine derivatives inhibit prolyl-tRNA synthetase
por: Keller, Tracy L., et al.
Publicado: (2012)

Evolution of acceptor stem tRNA recognition by class II prolyl-tRNA synthetase
por: An, Songon, et al.
Publicado: (2008)

Comparative Pharmacokinetics/Pharmacodynamics of Fixed-Dose Combination of Esomeprazole and Calcium Carbonate (AD-206) to the Conventional Esomeprazole
por: Bae, Sungyeun, et al.
Publicado: (2021)

Prolyl-tRNA synthetase as a novel therapeutic target in multiple myeloma
por: Kurata, Keiji, et al.
Publicado: (2023)

A fixed-dose combination tablet of gemigliptin and metformin sustained release has comparable pharmacodynamic, pharmacokinetic, and tolerability profiles to separate tablets in healthy subjects
por: Park, Sang-In, et al.
Publicado: (2015)

Correction: Prolyl-tRNA synthetase as a novel therapeutic target in multiple myeloma
por: Kurata, Keiji, et al.
Publicado: (2023)

Semimechanistic pharmacokinetic–pharmacodynamic model of tripegfilgrastim for pediatric patients after chemotherapy
por: Lee, Soyoung, et al.
Publicado: (2023)

Elucidating the path to Plasmodium prolyl-tRNA synthetase inhibitors that overcome halofuginone resistance
por: Tye, Mark A., et al.
Publicado: (2022)

Safety, tolerability, pharmacokinetic, and pharmacodynamic characteristics of vutiglabridin: A first‐in‐class, first‐in‐human study
por: Na, Joo Young, et al.
Publicado: (2022)

Glutamyl-prolyl-tRNA synthetase 1 coordinates early endosomal anti-inflammatory AKT signaling
por: Lee, Eun-Young, et al.
Publicado: (2022)

Comparison of Pharmacokinetic, Pharmacodynamic and Tolerability Profiles of CKD-11101, Darbepoetin Alfa (NESP(®)) Biosimilar, to Those of NESP(®) After a Single Subcutaneous or Intravenous Administration to Healthy Subjects
por: Jeon, Inseung, et al.
Publicado: (2021)

Crystal structure of human cytosolic aspartyl-tRNA synthetase, a component of multi-tRNA synthetase complex
por: Kim, Kyung Rok, et al.
Publicado: (2013)

Phosphocode-dependent glutamyl-prolyl-tRNA synthetase 1 signaling in immunity, metabolism, and disease
por: Lee, Eun-Young, et al.
Publicado: (2023)

Strictly Conserved Lysine of Prolyl-tRNA Synthetase Editing Domain Facilitates Binding and Positioning of Misacylated tRNA(Pro)
por: Bartholow, Thomas G., et al.
Publicado: (2014)

The zinc-binding domain of mammalian prolyl-tRNA synthetase is indispensable for catalytic activity and organism viability
por: Vasu, Kommireddy, et al.
Publicado: (2021)

Whole exome sequencing reveals mutations in NARS2 and PARS2, encoding the mitochondrial asparaginyl-tRNA synthetase and prolyl-tRNA synthetase, in patients with Alpers syndrome
por: Sofou, Kalliopi, et al.
Publicado: (2015)

Pharmacokinetics, pharmacodynamics, and tolerability of LC350189, a novel xanthine oxidase inhibitor, in healthy subjects
por: Yoon, Seonghae, et al.
Publicado: (2015)

Origin and Evolution of Glutamyl-prolyl tRNA Synthetase WHEP Domains Reveal Evolutionary Relationships within Holozoa
por: Ray, Partho Sarothi, et al.
Publicado: (2014)

Biochemical and Structural Characterization of Selective Allosteric Inhibitors of the Plasmodium falciparum Drug Target, Prolyl-tRNA-synthetase
por: Hewitt, Stephen Nakazawa, et al.
Publicado: (2016)

Discovery and pharmacological characterization of a new class of prolyl-tRNA synthetase inhibitor for anti-fibrosis therapy
por: Shibata, Akira, et al.
Publicado: (2017)

Double drugging of prolyl-tRNA synthetase provides a new paradigm for anti-infective drug development
por: Manickam, Yogavel, et al.
Publicado: (2022)

Cardiomyocyte-specific Loss of Glutamyl-prolyl-tRNA Synthetase Leads to Disturbed Protein Homeostasis and Dilated Cardiomyopathy
por: Wu, Jiangbin, et al.
Publicado: (2023)

Methionyl-tRNA Synthetase Regulates Lifespan in Drosophila
por: Suh, Yoon Seok, et al.
Publicado: (2020)

Pharmacokinetic and pharmacodynamic interactions between metformin and a novel dipeptidyl peptidase-4 inhibitor, evogliptin, in healthy subjects
por: Rhee, Su-jin, et al.
Publicado: (2016)

Targeting prolyl-tRNA synthetase via a series of ATP-mimetics to accelerate drug discovery against toxoplasmosis
por: Yogavel, Manickam, et al.
Publicado: (2023)

Adenosine-Mimicking Derivatives of 3-Aminopyrazine-2-Carboxamide: Towards Inhibitors of Prolyl-tRNA Synthetase with Antimycobacterial Activity
por: Pallabothula, Vinod Sukanth Kumar, et al.
Publicado: (2022)

Considerations for clinical evaluation of the effects of bariatric surgery on the pharmacokinetics of orally administered drugs
por: Bae, Sungyeun, et al.
Publicado: (2022)

A non-linear pharmacokinetic-pharmacodynamic relationship of metformin in healthy volunteers: An open-label, parallel group, randomized clinical study
por: Chung, Hyewon, et al.
Publicado: (2018)

Bacterial Aspartyl-tRNA Synthetase Has Glutamyl-tRNA Synthetase Activity
por: Rathnayake, Udumbara M., et al.
Publicado: (2019)

Aminoacyl-tRNA synthetases of the multi-tRNA synthetase complex and their role in tumorigenesis
por: Khan, Krishnendu, et al.
Publicado: (2022)

Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Dupilumab in Healthy Adult Subjects
por: Li, Zhaoyang, et al.
Publicado: (2020)

Glutamyl-Prolyl-tRNA Synthetase Regulates Epithelial Expression of Mesenchymal Markers and Extracellular Matrix Proteins: Implications for Idiopathic Pulmonary Fibrosis
por: Song, Dae-Geun, et al.
Publicado: (2018)

Towards Novel 3-Aminopyrazinamide-Based Prolyl-tRNA Synthetase Inhibitors: In Silico Modelling, Thermal Shift Assay and Structural Studies
por: Pang, Luping, et al.
Publicado: (2021)

Repositioning and Characterization of 1-(Pyridin-4-yl)pyrrolidin-2-one Derivatives as Plasmodium Cytoplasmic Prolyl-tRNA Synthetase Inhibitors
por: Okaniwa, Masanori, et al.
Publicado: (2021)

Identification of glutamyl-prolyl-tRNA synthetase as a new therapeutic target in hepatocellular carcinoma via a novel bioinformatic approach
por: Shu, Jinyong, et al.
Publicado: (2023)

Pharmacokinetics, safety and tolerability of valbenazine in Korean CYP2D6 normal and intermediate metabolizers
por: Chung, Woo Kyung, et al.
Publicado: (2022)

Aminoacyl-tRNA synthetases
por: Rubio Gomez, Miguel Angel, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_a80o4mbemhrgmkmsp7slkv3e3e